Semaglutide - two important news that you couldn't miss

No 1: Semaglutide is found as a breakthrough therapy for the treatment of NASH (non-alcoholic steatohepatitis)!

On October 30, 2020, Novo Nordisk announced its results for the first three quarters of fiscal 2020. In this quarterly report conference call, Novo Nordisk said: The US FDA has granted Semaglutide the qualification for breakthrough therapy for the treatment of NASH (non-alcoholic steatohepatitis), based on previously disclosed Phase 2 clinical data. Novo Nordisk expects to start a phase 3 clinical trial of Semaglutide for the treatment of NASH in 2021.

No 2: Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy!

BAGSVÆRD, Denmark, Nov. 5, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT. The STEP 3 phase 3a trial investigated the efficacy and safety of once-weekly semaglutide 2.4 mg after 68 weeks of treatment compared with placebo both as adjunct to IBT, which consisted of 30 counselling sessions with a registered dietitian over 68 weeks, plus a reduced-calorie diet and increased physical activity. Trial participants were adults with obesity or overweight with at least one weight-related co-morbidity and without type 2 diabetes.

Based on the primary statistical approach, people treated with once-weekly semaglutide 2.4 mg in addition to IBT lost an average of 16.0% of their body weight from baseline, compared with 5.7% for those who received placebo plus IBT. Furthermore, more people treated with semaglutide 2.4 mg plus IBT lost greater than or equal to 5% of their body weight compared to placebo plus IBT (87% vs 48%, respectively).